Compare TGL & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGL | RLAY |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 1.5B |
| IPO Year | 2022 | 2020 |
| Metric | TGL | RLAY |
|---|---|---|
| Price | $7.06 | $8.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 2.5M | 2.3M |
| Earning Date | 02-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,305,713.00 | ★ $8,355,000.00 |
| Revenue This Year | N/A | $20.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.51 | $1.78 |
| 52 Week High | $780.00 | $9.04 |
| Indicator | TGL | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 53.65 |
| Support Level | $5.75 | $8.25 |
| Resistance Level | $7.78 | $8.58 |
| Average True Range (ATR) | 1.39 | 0.46 |
| MACD | -0.42 | -0.05 |
| Stochastic Oscillator | 41.68 | 33.46 |
Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: payment processing and e-commerce operation in its ZCITY platform, and customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).